First results from the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) shows no benefit of adding lapatinib to standard trastuzumab adjuvant therapy in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Neither a specific diagnostic approach nor “a gender-driven” therapy is currently available for women with lung cancer, according to an expert who discussed existing assumptions and evidence at the recent Asia Pacific Lung Cancer Conference 2016.